FM in the context of chemotherapy means a chemotherapy regimen used as first-line therapy in indolent lymphomas. In combination with rituximab it is called R-FM or RFM or FM-R or FMR.
The [R]-FM regimen consists of:
- (R)ituximab - an anti-CD20 monoclonal antibody that is able to kill both normal B cells and malignant ones;
- (F)ludarabine - an antimetabolite;
- (M)itoxantrone - a synthetic anthracycline analogue (an anthraquinone) that is able to intercalate DNA and prevent mitosis.[1]
This regimen is also sometimes used in some autoimmune disorders that are inherently sensitive to rituximab, fludarabine and mitoxantrone in monotherapies (e.g. multiple sclerosis).
Dosing regimen
edit| Drug | Dose | Mode | Days |
|---|---|---|---|
| (R)ituximab | 375 mg/m2 | IV infusion | Day 1 |
| (F)ludarabine | 25 mg/m2 | IV infusion | Days 1-3 |
| (M)itoxantrone | 10 mg/m2 | IV infusion | Day 1 |